Nuo Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
Nuo Therapeutics announced strong first quarter 2026 financial results, with total revenues soaring 169% year-over-year, driven by significant growth in its Aurix product line.
OQB
Nuo Therapeutics, Inc. has entered into a Loan and Security Agreement for up to $1.6 million, accompanied by significant warrant issuances and high interest rates, to fund general working capital.
OQB
Nuo Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, electing four directors, ratifying MaloneBailey LLP as auditor, and approving executive compensation on an advisory basis.
OQB
Nuo Therapeutics, Inc. announced salary increases for its CEO/CFO and CSO/COO, citing improved business conditions, and set its 2025 Annual Meeting for December 16, 2025.
OQB
Nuo Therapeutics and Smith+Nephew have amended their distribution agreement to include an interim sales agency arrangement for Nuo Aurix branded products.
OQB
Nuo Therapeutics has successfully completed a private placement, raising $849,125 through the sale of common stock to accredited investors.
OQB
Pacific Medical exercised a warrant to purchase Nuo Therapeutics stock, resulting in the issuance of 356,889 shares and $151,200 in proceeds for Nuo.
OQB
Nuo Therapeutics has dismissed Marcum LLP as its independent auditor and engaged MaloneBailey, LLP, citing material weaknesses in internal controls related to accounting and financial reporting resources.
OQB
Nuo Therapeutics has successfully completed a private placement, raising $650,875 through the sale of common stock to accredited investors, including company insiders.
OQB
Nuo Therapeutics has announced a delay in filing its annual report on Form 10-K due to an ongoing review by its independent accounting firm, with a new expected filing date of April 19, 2024.